Skip to main content
!
Phase III+: The University is open for expanded research operations; only authorized personnel will be admitted on campus. More info here.
!
Phase III+: The University is open for expanded research operations; only authorized personnel will be admitted on campus. More info here.
!
Phase III+: The University is open for expanded research operations; only authorized personnel will be admitted on campus. More info here.

Philanthropy News

SARS-CoV-2 in human intestine

ROCKEFELLER UNIVERSITY RECEIVES A $75 MILLION GRANT FROM THE STAVROS NIARCHOS FOUNDATION TO ESTABLISH AN INSTITUTE FOR GLOBAL INFECTIOUS DISEASE RESEARCH

NEW YORK, NY, September 29, 2022 — The Rockefeller University is pleased to announce the launch of the Stavros Niarchos Foundation (SNF) Institute for Global Infectious Disease Research. Made possible by a $75 million grant from the Stavros Niarchos Foundation (SNF), the new institute will accelerate the development of innovative therapies for emerging pathogens, such as novel coronaviruses, as well as endemic microbes, like tuberculosis, that threaten global health.

“The COVID-19 pandemic has underscored the critical need for investment in infectious disease research to understand the biology of pathogens and their interactions with host species and to enable the development of broadly effective and durable vaccines and therapeutics,” said Richard P. Lifton, the university’s president. “The SNF Institute for Global Infectious Disease Research will accelerate biomedical innovation, provide scientific education, and raise public awareness in the global community.”

SNF is a longstanding partner of The Rockefeller University. The Foundation helped fund a major campus expansion, which opened in 2019, and in March 2020, SNF was one of the earliest funders of Rockefeller’s COVID-19 research program. The SNF Institute for Global Infectious Disease Research at Rockefeller grew from that early program.

“To rise to the health challenges we face today, our approach must be unified across disciplines and borders,” said SNF Co-President Andreas Dracopoulos. “The new institute will not only lay the scientific foundation for better prevention and treatment of infectious diseases but will also help to ensure that those treatments are made available globally and equitably.”

While coronaviruses will be a strong focus, the new institute will also support research on other pathogens that pose a challenge to world health. Tick-borne encephalitis is one example. The disease is on the rise in Europe due in part to warming temperatures that help to expand the range of ticks carrying the virus. A collaboration between Rockefeller investigators and other scientists in the United States, Switzerland, and the Czech Republic is showing promising results for an effective vaccine.

The institute will be led by Charles Rice, Rockefeller’s Maurice R. and Corinne P. Greenberg Professor in Virology. Dr. Rice shared the Nobel Prize for Physiology or Medicine in 2020 for foundational research that led to the development of a therapeutic for Hepatitis C. “Emerging pathogens will keep coming. We need coordinated, intensive research in order to be prepared,” Rice says. “The new institute will provide us with the means to encourage global collaborations, and a capability to support everything from basic infectious disease research to clinical development.” Dr. Rice chaired the New York State’s COVID-19 Clinical Advisory Task Force during the pandemic.

Michel Nussenzweig, a physician-scientist and head of Rockefeller’s Laboratory of Molecular Immunology, will serve as co-director, guiding immunological studies. Barry Coller, Physician-in-Chief of The Rockefeller University Hospital, will act as co-director for clinical studies.

Dozens of Rockefeller laboratories will contribute to the institute’s efforts to characterize pathogens, understand the human body’s immune response, and develop vaccines and therapeutics. Participating scientists include virologists, immunologists, structural biologists, geneticists, and physician-scientists.

“We are a global community when it comes to infectious diseases,” Rice says. “We have to be willing to tackle global challenges and encourage research collaboration around the world.”

About the Stavros Niarchos Foundation (SNF)

The Stavros Niarchos Foundation (SNF) is one of the world’s leading private, international philanthropic organizations, making grants to nonprofit organizations in the areas of arts and culture, education, health and sports, and social welfare. SNF funds organizations and projects worldwide that aim to achieve a broad, lasting, and positive impact for society at large, and exhibit strong leadership and sound management. The Foundation also supports projects that facilitate the formation of public-private partnerships as an effective means for serving public welfare.

Since 1996, the Foundation has committed more than $3.4 billion through over 5,100 grants to nonprofit organizations in more than 135 countries around the world.

Learn more at SNF.org.

DOWNLOAD PDF


Contact

Maren E. Imhoff
Senior Vice President for Development
The Rockefeller University
1230 York Avenue, Box 164
New York, NY  10065


Related Content

Charles M. RiceCharles M. Rice, Ph.D.
Maurice R. and Corinne P. Greenberg Professor in Virology
Laboratory of Virology Infectious Disease

Michel C. NussenzweigMichel C. Nussenzweig, M.D., Ph.D.
Zanvil A. Cohn and Ralph M. Steinman Professor
Investigator, Howard Hughes Medical Institute
Senior Physician
Laboratory of Molecular Immunology

Barry S. CollerBarry S. Coller, M.D.
David Rockefeller Professor
Physician in Chief
Vice President for Medical Affairs
Allen and Frances Adler Laboratory of Blood and Vascular Biology